Sugar, its salt, or solvate of them

Oligosaccharides with a 6-sulfo-N-acetylamino sugar linkage stimulate immune response by promoting IgA secretion, addressing the immunostimulatory limitations of galacto-N-biose and enhancing mucosal immunity.

JP2024167701APending Publication Date: 2024-12-04WAKAYAMA UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023083953
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2024-12-04

AI Technical Summary

Technical Problem

Galacto-N-biose, despite being a prebiotic, lacks an immunostimulatory effect such as promoting IgA secretion, limiting its ability to enhance mucosal immunity and resistance to pathogen infection.

Method used

Development of oligosaccharides represented by the formulas Galβ(1→3)Xxx1 or Galβ(1→3)Xxx1-Xxx2, where Xxx1 is a 6-sulfo-N-acetylamino sugar, and Xxx2 is any sugar, which exhibit immunostimulatory effects through the promotion of IgA secretion.

Benefits of technology

The developed oligosaccharides effectively stimulate the immune system by increasing IgA production, enhancing mucosal immunity, and providing resistance to pathogens, even in the absence of intestinal bacteria.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167701000003
    Figure 2024167701000003
  • Figure 2024167701000004
    Figure 2024167701000004
  • Figure 2024167701000001
    Figure 2024167701000001
Patent Text Reader

Abstract

To provide an oligosaccharide having adjuvanticity.SOLUTION: The present invention provides a sugar represented by Galβ(1→3) Xxx1 [Xxx1 denotes 6-sulfo-N-acetylamino sugar] or Galβ(1→3) Xxx1-Xxx2 [Xxx1 denotes 6-sulfo-N-acetylamino sugar and Xxx2 denotes any sugar], its salt, and a solvate of them.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a sugar, a salt thereof, or a solvate thereof, etc. [Background technology]

[0002] In living organisms, mucous membranes are exposed to microorganisms such as bacteria and viruses, various antigens, toxins, etc., and therefore defense mechanisms against these exist. One of these is known to be the mucosal immune mechanism, such as intestinal immunity. For example, in the intestinal mucosa, immunoglobulin A (IgA) is secreted by immune cells in the Peyer's patches, which prevents the invasion of microorganisms through the intestinal mucosa, neutralizes toxins, prevents the invasion of allergens, and controls intestinal symbiotic bacteria. Therefore, it is believed that promoting the secretion of immunoglobulin A will activate mucosal immunity and increase resistance to pathogen infections and poisoning caused by their toxins.

[0003] Galacto-N-biose has been known as a prebiotic for some time. For example, Non-Patent Document 1 describes that lactic acid bacteria grow in the presence of galacto-N-biose. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Appl Microbiol Biotechnol. 2017 Jan;101(1):205-215. doi: 10.1007 / s00253-016-7882-0. Epub 2016 Oct 7. Summary of the Invention [Problem to be solved by the invention]

[0005] If an oligosaccharide that can be used as a prebiotic also has an immunostimulating effect, it is expected to exert both beneficial effects by promoting the proliferation of useful intestinal bacteria and an immunostimulating effect. However, galacto-N-biose does not have an immunostimulating effect such as promoting IgA secretion.

[0006] Therefore, an objective of the present invention is to provide oligosaccharides having immunopotentiating effects. [Means for solving the problem]

[0007] In view of the above problems, the present inventors have conducted intensive research and have discovered Galβ(1→3)Xxx 1 [Xxx 1 indicates 6-sulfo-N-acetylamino sugar. ] or Galβ(1→3)Xxx 1 -Xxx 2 [Xxx 1 denotes 6-sulfo-N-acetylamino sugar, and Xxx 2 represents any sugar.], its salt, or a solvate thereof, the inventors have found that the above-mentioned problems can be solved. Based on this finding, the inventors have conducted further research and have completed the present invention. That is, the present invention includes the following aspects.

[0008] Term 1. Galβ(1→3)Xxx 1 [Xxx 1 indicates 6-sulfo-N-acetylamino sugar. ] or Galβ(1→3)Xxx 1 -Xxx 2 [Xxx 1 denotes 6-sulfo-N-acetylamino sugar, and Xxx 2 represents any sugar.], a salt thereof, or a solvate thereof.

[0009] Section 2. Xxx 1 Item 2. The sugar, salt thereof, or solvate thereof according to Item 1, wherein the sugar, salt thereof, or solvate thereof is 6-sulfo-N-acetylgalactosamine.

[0010] Item 3. The sugar, salt thereof, or solvate thereof according to Item 1, wherein the number of monosaccharide molecules constituting the sugar is 2 to 20.

[0011] Item 4. The saccharide, salt thereof, or solvate thereof according to Item 3, wherein the number of molecules is 2 to 5.

[0012] Item 5. A composition comprising at least one selected from the group consisting of the saccharide according to any one of items 1 to 4, a salt thereof, and a solvate thereof.

[0013] Item 6. The composition according to Item 5, which is in an orally ingestible form.

[0014] Item 7. The composition according to Item 5, which is a food composition, a food additive, a health promoting agent, a nutritional supplement, a medicine, or a reagent.

[0015] Item 8. The composition according to Item 5, for use in at least one selected from the group consisting of immunostimulation, protection against infection, and promotion of IgA production.

[0016] Item 9. Galactose donor and Xxx 1 [Xxx 1 represents 6-sulfo-N-acetylamino sugar.] or Xxx 1 -Xxx 2 [Xxx 1 denotes 6-sulfo-N-acetylamino sugar, and Xxx 2 represents any sugar.] in the presence of β-galactosidase. Effect of the Invention

[0017] According to the present invention, it is possible to provide oligosaccharides having immunopotentiating activity. [Brief description of the drawings]

[0018] [Figure 1]The results of Test Example 1 are shown. The genes to be measured are shown above the graph. The vertical axis shows the gene expression level. On the horizontal axis, 6S_GNB shows the 6-sulfo-galacto-N-biose-added group, GNB shows the galacto-N-biose-added group, and control shows the non-added group. Groups with different alphabets displayed above indicate significance (P<0.01). [Diagram 2] 1 shows the results of Test Example 2. The vertical axis shows the amount of IgA in the supernatant. On the horizontal axis, 6S-GNB shows the 6-sulfo-galacto-N-biose-added group, GNB shows the galacto-N-biose-added group, and control shows the non-added group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] In this specification, the expressions "contain" and "comprise" include the concepts of "contain", "include", "consist essentially of" and "consist only of".

[0020] 1. Oligosaccharides In one aspect, the present invention relates to a Galβ(1→3)Xxx 1 Or Galβ(1→3)Xxx 1 -Xxx 2 The present invention relates to a saccharide represented by the formula (I), a salt thereof, or a solvate thereof (collectively referred to as "oligosaccharide of the present invention" in this specification). This will be explained below.

[0021] Xxx 1indicates 6-sulfo-N-acetylaminosugar. 6-sulfo-N-acetylaminosugar is a sugar (amino sugar) in which the hydroxy group (-OH) at the 6-position of a hexose is replaced with -OS(=O)2-OH and the hydroxy group at positions other than the 6-position and 3-position (typically the hydroxy group at the 2-position) is replaced with an amino group, and is not particularly limited insofar as the amino group is substituted with an acetyl group. Specific examples of 6-sulfo-N-acetylaminosugar include 6-sulfo-N-acetylgalactosamine, 6-sulfo-N-acetylglucosamine, and 6-sulfo-N-acetylmannosamine. Among these, from the viewpoint of immunopotentiation, preferred are 6-sulfo-N-acetylgalactosamine and 6-sulfo-N-acetylglucosamine, and particularly preferred are 6-sulfo-N-acetylgalactosamine.

[0022] Xxx 2 represents any sugar. Examples of the arbitrary sugar include monosaccharides and oligosaccharides.

[0023] The monosaccharide is not particularly limited and may be any known monosaccharide, such as heptose, hexose, pentose, tetraose, or triose, with hexose being preferred.

[0024] Examples of hexoses include galactose, glucose, N-acetylglucosamine, N-acetylgalactosamine, mannose, fructose, allose, talose, gulose, altrose, idose, psicose, sorbose, and tagatose. In addition, some of the hydroxyl groups in these sugars may be reduced and replaced with hydrogen atoms, or some of the hydroxyl groups may be protected with a known protecting group or replaced with a functional group such as a sulfate group.

[0025] Oligosaccharides are sugars in which two or more monosaccharide molecules are linked to one molecule by glycosidic bonds. The number of monosaccharide molecules constituting an oligosaccharide may be, for example, 2 to 20, preferably 2 to 10, more preferably 2 to 5, and even more preferably 2 to 3. The type of monosaccharide constituting an oligosaccharide is not particularly limited, and the monosaccharides listed above may be used. The combination of monosaccharides constituting an oligosaccharide is also not particularly limited. Specific examples of oligosaccharides include oligosaccharides having two constituent monosaccharide molecules (e.g., lactose, Galβ(1→3)GalNAc, Galβ(1→6)GalNAc, Galβ(1→4)GlcNAc, Galβ(1→6)GlcNAc, sucrose, maltose, trehalose, turanose, cellobiose, etc.), oligosaccharides having three constituent monosaccharide molecules (e.g., raffinose, melezitose, maltotriose, etc.), oligosaccharides having four constituent monosaccharide molecules (e.g., acarbose or stachyose), and oligosaccharides having five or more constituent monosaccharide molecules, and among these, oligosaccharides having two constituent monosaccharide molecules are preferred.

[0026] Galβ(1→3)Xxx 1 is a 6-sulfo-N-acetylaminosugar (Xxx 1 ) is linked by a β-glycosidic bond to the 3-hydroxy group of the 6-sulfo-N-acetylamino sugar. The structural formula (A) (6-sulfo-galacto-N-biose) when the 6-sulfo-N-acetylamino sugar is 6-sulfo-N-acetylgalactosamine (GalNAc) and the structural formula (B) (6-sulfo-lacto-N-biose) when the 6-sulfo-N-acetylamino sugar is 6-sulfo-N-acetylglucosamine (GlcNAc) are shown below.

[0027] [ka]

[0028] [ka]

[0029] Galβ(1→3)Xxx 1 -Xxx 2 Galβ(1→3)Xxx 1 Xxx 1 Hydroxy group of Xxx 2 It is a sugar that is linked to the hydroxyl group of the β-galactosidase by a glycosidic bond. The glycosidic bond is in the form of Galβ(1→3)Xxx. 1 -Xxx 2 The bond is not particularly limited as long as it can be assimilated by the enterobacteria. The bond can be, for example, a bond that can be cleaved in vivo (particularly in the digestive tract), and specific examples thereof include α-1,4-glycosidic bond and β-1,4-glycosidic bond.

[0030] From the viewpoint of immunopotentiating effect, the number of monosaccharide molecules constituting the oligosaccharide of the present invention is, for example, 2 to 20, preferably 2 to 10, more preferably 2 to 5, and even more preferably 2 to 3. From the viewpoint of immunopotentiating effect, the oligosaccharide of the present invention is particularly preferably Galβ(1→3)Xxx 1 It is.

[0031] The salt of the oligosaccharide of the present invention is not particularly limited, and may be, for example, a pharma- ceutically acceptable salt. The salt may be either an acid salt or a basic salt. Examples of acid salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, nitrate, and phosphate; organic acid salts such as acetate, propionate, tartrate, fumarate, maleate, malate, citrate, methanesulfonate, and paratoluenesulfonate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt; salts with ammonia; salts with organic amines such as morpholine, piperidine, pyrrolidine, monoalkylamine, dialkylamine, trialkylamine, mono(hydroxyalkyl)amine, di(hydroxyalkyl)amine, and tri(hydroxyalkyl)amine. Typically, the salt of the oligosaccharide of the present invention is a salt with a sulfo group in 6-sulfo-N-acetylamino sugar (for example, an alkali metal salt such as sodium salt).

[0032] The solvate of the oligosaccharide of the present invention is not particularly limited and may be, for example, a solvate with a pharma- ceutically acceptable solvent, such as water or a pharma-ceutically acceptable organic solvent (e.g., ethanol, glycerol, acetic acid, etc.).

[0033] The oligosaccharides of the present invention may, for example, be a galactose donor and a Xxx 1 Or Xxx 1 -Xxx 2 The compound can be produced by a method comprising the step of reacting a saccharide represented by the formula:

[0034] Xxx 1 Or Xxx 1 -Xxx 2 The sugar represented by the formula (I) is as described above.

[0035] Xxx 1 and Xxx 1 -Xxx 2The sugar represented by is an N-acetylamino sugar, or an N-acetylamino sugar with a hydroxy group and Xxx 2 and the hydroxy group of the above linked by a glycosidic bond with a sulfation reagent (for example, sulfur trioxide pyridine complex, sulfur trioxide trimethylamine complex, etc.).

[0036] The galactose donor is not particularly limited, and the galactose donors described in JP 2017-195793 A can be widely used. Specific examples include p-nitrophenyl-β-D-galactopyranoside, o-nitrophenyl-β-D-galactopyranoside, 4-methoxyphenyl-β-D-galactopyranoside, phenyl-β-D-galactopyranoside, lacto-N-biose, galactobiose, and the like.

[0037] The β-galactosidase is not particularly limited, but from the viewpoint of reaction efficiency, the β-galactosidase described in JP 2017-195793 A is preferably used. Particularly preferred is the β-galactosidase derived from the Bacillus genus bacteria GS-MAIU strain (Patent Organism Depositary Center Accession Number: NITE P-02240).

[0038] The reaction can be carried out according to or in accordance with the method described in JP 2017-195793 A.

[0039] After the reaction, the solution containing the oligosaccharide of the present invention obtained by the reaction may be subjected to a purification step. The purification step may be a known method (liquid separation, distillation, chromatography, recrystallization, etc.). In addition, the excess sugar acceptor may be recovered and reused after the reaction is completed.

[0040] 2.Applications The oligosaccharide of the present invention can exert at least one effect selected from the group consisting of immunostimulation, protection against infection, and promotion of IgA production.

[0041] Immunostimulation can prevent microbial infections and improve microbial infection symptoms. Immunostimulation can also increase the immunogenicity of vaccine antigens. Promotion of IgA (secretory IgA) production makes it possible to defend against microbial infections, neutralize toxins, block the invasion of allergens, and control intestinal symbiotic bacteria.

[0042] The oligosaccharides of the present invention can promote the secretion of IgA (secretory IgA) onto, for example, mucosa (e.g., buccal mucosa, gastric mucosa, intestinal mucosa, olfactory epithelium, oral mucosa, endometrium, etc., preferably intestinal mucosa).

[0043] The oligosaccharides of the present invention can exert the above-mentioned effects even in the absence of intestinal bacteria, and therefore can effectively exert the above-mentioned effects on cells, mucosa, or specimens (such as the elderly or those taking antibiotics) that retain a small amount (or no) of intestinal bacteria.

[0044] Examples of microorganisms include viruses and bacteria.

[0045] Examples of viruses include, but are not limited to, influenza viruses (e.g., types A and B), rubella viruses, Ebola viruses, coronaviruses (e.g., SARS coronavirus 2 (SARS-CoV-2)), measles viruses, varicella-zoster viruses, herpes simplex viruses, mumps viruses, arboviruses, respiratory syncytial viruses, SARS viruses, hepatitis viruses (e.g., hepatitis B viruses, hepatitis C viruses), yellow fever viruses, AIDS viruses, rabies viruses, hantaviruses, dengue viruses, Nipah viruses, and lyssaviruses; and non-enveloped viruses (viruses that do not have an envelope), such as adenoviruses, noroviruses, rotaviruses, human papillomaviruses, polioviruses, enteroviruses, coxsackieviruses, human parvoviruses, encephalomyocarditis viruses, and rhinoviruses.

[0046] Examples of bacteria include, but are not limited to, Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Salmonella, Helicobacter pylori, Clostridium perfringens, Clostridium botulinum, Campylobacter, Escherichia coli, Staphylococcus aureus, Streptococcus cereus, Vibrio parahaemolyticus, Propionibacterium acnes, Clostridium faecalis, Clostridium difficile, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Klebsiella pneumoniae, Koinebacterium, Streptococcus hemolyticus, Pseudomonas aeruginosa, Staphylococcus aureus, Mycoplasma, Candida, and Aspergillus.

[0047] In one aspect, the present invention relates to a composition (sometimes referred to herein as the "composition of the present invention") containing the oligosaccharide of the present invention.

[0048] The composition of the present invention preferably contains the oligosaccharide of the present invention as a purified product.The content of the oligosaccharide of the present invention, which is the active ingredient contained in the composition of the present invention, can be preferably 30% by mass or more, more preferably 50% by mass or more, even more preferably 70% by mass or more, even more preferably 80% by mass or more, particularly preferably 90% by mass or more, and particularly preferably 95% by mass or more, based on 100% by mass of the saccharide contained in the composition of the present invention.

[0049] The composition of the present invention and the oligosaccharide of the present invention can be used in various fields, for example, as a food additive, a food composition (including health enhancers and nutritional supplements (supplements, etc.)), a medicine, a reagent, and the like.

[0050] The use of the composition of the present invention and the oligosaccharide of the present invention is not particularly limited, and an appropriate use mode can be adopted depending on the type. The drug of the present invention can be used, for example, in vitro (e.g., added to a culture medium for cultured cells) or in vivo (e.g., administered to an animal) depending on the purpose.

[0051] The compositions of the present invention and the oligosaccharides of the present invention are not particularly limited to mammals, and examples of such mammals include humans, monkeys, mice, rats, dogs, cats, rabbits, pigs, horses, cows, sheep, goats, and deer. Examples of such cells include animal cells. The types of cells are also not particularly limited, and examples of such cells include blood cells, hematopoietic stem cells and progenitor cells, gametes (sperm, eggs), fibroblasts, epithelial cells, vascular endothelial cells, nerve cells, hepatocytes, keratinocytes, muscle cells, epidermal cells, endocrine cells, ES cells, iPS cells, tissue stem cells, and cancer cells.

[0052] The composition of the present invention and the oligosaccharide of the present invention are usually taken orally, but are not limited thereto. The composition of the present invention and the oligosaccharide of the present invention can be administered orally; enterally, such as by tube feeding or enema; or parenterally, such as intravenously, intraarterially, intramuscularly, intracardially, subcutaneously, intradermally, intraperitoneally, or nasally.

[0053] The form of the composition of the present invention is not particularly limited, and may take a form that is commonly used for each application depending on the application.

[0054] When the composition of the present invention is used as a food additive, a health enhancer, a nutritional supplement (such as a supplement), etc., the form of the composition may be, for example, a tablet (including orally disintegrating tablets, chewable tablets, effervescent tablets, lozenges, jelly-like drops, etc.), a pill, a granule, fine granules, a powder, a hard capsule, a soft capsule, a dry syrup, a liquid (including drinks, suspensions, and syrups), a jelly, etc.

[0055] When the composition of the present invention is intended for use as a medicine, examples of the form of the composition include oral preparation forms such as tablets (including orally disintegrating tablets, chewable tablets, effervescent tablets, lozenges, jelly drops, etc.), pills, granules, fine granules, powders, hard capsules, soft capsules, dry syrups, liquids (including drinks, suspensions, syrups), and jellies; and parenteral preparation forms such as injectable preparations (for example, drip injections (for example, intravenous drip preparations), intravenous injections, intramuscular injections, subcutaneous injections, and intradermal injections), topical preparations (for example, ointments, poultices, and lotions), suppositories, inhalants, eye drops, eye ointments, nasal drops, ear drops, and liposomes.

[0056] The form of the composition of the present invention, when used as a food composition, may be liquid, gel or solid foods, for example, (1) beverages such as soft drinks, carbonated drinks, fruit drinks, vegetable juices, lactic acid bacteria drinks, dairy drinks, soy milk, mineral water, tea drinks, coffee drinks, sports drinks, alcoholic drinks, jelly drinks, etc., (2) vegetable processed products such as tomato puree, canned mushrooms, dried vegetables, pickles, etc., and (3) fruit processed products such as dried fruit, jam, fruit puree, canned fruit, etc. (4) Spices such as curry powder, wasabi, ginger, spice blends, seasoning powder, etc.; (5) Noodles (including fresh and dried noodles) such as pasta, udon, soba, ramen, macaroni, etc.; (6) Breads such as white bread, sweet bread, cooked bread, donuts, etc.; (7) Pregelatinized rice, oatmeal, wheat gluten, batter flour, etc.; (8) Baked goods, biscuits, rice sweets, candy, chocolate, chewing gum, snacks, frozen sweets, candied sweets, Japanese fresh sweets, Western fresh sweets, semi-fresh sweets (9) bean products such as red beans, tofu, natto, soybean flour, yuba, boiled beans, peanuts, etc.; (10) honey, royal jelly processed foods; (11) meat products such as ham, sausage, bacon, etc.; (12) dairy products such as yogurt, pudding, condensed milk, cheese, fermented milk, butter, ice cream, etc.; (13) processed egg products; (14) processed fish such as dried fish, kamaboko, chikuwa, fish sausage, etc., processed seaweed such as dried wakame, kelp, tsukudani, etc., and cod roe. (15) seasonings such as dashi stock, soy sauce, vinegar, mirin, consomme base, Chinese base, concentrated dashi stock, dressing, mayonnaise, ketchup, miso, etc., edible oils and fats such as salad oil, sesame oil, linoleic oil, diacylglycerol, safflower oil, etc., (16) cooked and semi-cooked foods such as soups (including powders and liquids), side dishes, retort foods, refrigerated foods, semi-cooked foods (for example, seasonings for seasoned rice and seasonings for crab and egg omelet), etc.

[0057] The composition of the present invention may further contain other components as necessary. The other components are not particularly limited as long as they can be blended into food additives, food compositions, medicines, reagents, health enhancers, nutritional supplements (supplements, etc.), and examples thereof include amino acids, alcohols, polyhydric alcohols, polymeric compounds such as sugars, gums, and polysaccharides, surfactants, preservatives, antibacterial agents, and bactericides, pH adjusters, chelating agents, antioxidants, enzyme components, binders, disintegrants, lubricants, fluidizing agents, and refreshing agents, as well as minerals, cell activators, nutritional tonics, excipients, thickeners, stabilizers, preservatives, isotonicity agents, dispersants, adsorbents, disintegration aids, wetting agents or wetting regulators, moisture-proofing agents, colorants, flavorings or fragrances, fragrances, reducing agents, solubilizers, dissolution aids, foaming agents, thickening agents or thickening agents, solvents, bases, emulsifiers, plasticizers, buffers, and glossing agents.

[0058] The content of the active ingredient in the composition of the present invention depends on the application, mode of use, state of the subject of application, etc., and is not limited, and can be, for example, 0.0001 to 100% by mass, preferably 0.001 to 50% by mass. The content, calculated as dry weight, can be, for example, 50% by mass or more, 60% by mass or more, 70% by mass or more, 80% by mass or more, 90% by mass or more, 95% by mass or more, or 99% by mass or more.

[0059] The application amount (e.g., administration, ingestion, inoculation, etc.) of the composition of the present invention and the oligosaccharide of the present invention is not particularly limited as long as it is an effective amount that exerts its effect, and is usually 0.1 to 10,000 mg / kg body weight per day as the dry weight of the oligosaccharide of the present invention. The above application amount is preferably applied once or more (e.g., 1 to 3 times) per day, and can be appropriately increased or decreased depending on age, pathological condition, and symptoms. EXAMPLES

[0060] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.

[0061] Synthesis Example 1. Synthesis of 6-sulfo-N-acetylgalactosamine (6sulfo GalNAc) N-acetylgalactosamine (72 mg, 0.30 mmol) and sulfur trioxide pyridine complex (48 mg, 0.30 mmol) were dissolved in DMF (3.6 mL) and stirred at room temperature for 24 hours. After the reaction was completed, the mixture was subjected to a gel filtration column (Sephadex G10) to obtain the desired 6-sulfo-N-acetylgalactosamine (13.5 mg).

[0062] Synthesis Example 2. Synthesis of Galβ(1→3)6sulfo GalNAc (6-sulfo-galacto-N-biose) PNP-galactose (27.3 mg, 90.6 μmol) and 6-sulfo N-acetylgalactosamine (292.8 mg, 0.90 mmol) were dissolved in 600 μL of 50 mM phosphate buffer (pH = 6.0), and β-galactosidase (155 μL, 30 mU, derived from Bacillus sp. (GS-MAIU strain (Patent Biological Deposit Center Accession Number: NITE P-02240))) was added and incubated at 37 ° C for 48 hours. After the reaction was completed, the mixture was heated at 100 ° C for 3 minutes and centrifuged at 15000 × g for 5 minutes. The supernatant was applied to a gel filtration column (Sephadex G10) to obtain the desired 6-sulfo-galacto-N-biose (12.5 mg, 42.8%). 1 H-NMR (D2O) δ5.11 (d, 1H, J = 4.0 Hz), 4.61 (d, 1 H, J = 8.0 Hz), 4.39 (d, 1 H, J = 7.6 Hz), 4.33 (d, 1 H, J = 7.3 Hz), 4.27-4.24 (m), 4.20-4.17 (m), 4.12-4.03 (m), 3.96-3.74 (m), 3.68-3.59 (m), 3.56-3.49 (m), 3.41 (dd, 1 H, J = 8.0 Hz, J = 10.4 Hz), 1.92 (s, 3 H).

[0063] Synthesis Example 3. Synthesis of Galβ(1→3) GalNAc (galacto-N-biose) β-PNP-galactose (5 mg, 16.6 μmol) was dissolved in 495 μL of distilled water. Next, 100 μL of β-galactosidase (derived from Bacillus sp. (GS-MAIU strain (Patent Biological Depository Center accession number: NITE P-02240)) solution and 2.5 mL of N-acetylgalactosamine solution (50 mM Tris-HCl buffer (pH 8.0)) (N-acetylgalactosamine: 200 mg, 0.91 mmol) were added and incubated at 37°C for 48 h. After the reaction was completed, the reaction was stopped by heating at 100°C for 3 minutes to inactivate the enzyme. The reaction solution was desalted and filtered to remove insoluble components, and then applied to a GL Sciences (HPLC system PLC761) Inertsil Amide 5 μm (14 x 250 mm) column (column temperature: 40°C, eluent: acetonitrile / water = 7 / 3, flow rate: 9.5 mL / min) and detected by UV-215 nm for galacto-N-biose (4.93 mg, 12.7 μmol, 77.5%) was obtained. 1 H-NMR (D2O) δ5.01 (d, 1H, J = 3.6 Hz), 4.50 (d, 1 H, J = 8.0 Hz), 4.30 (d, 1 H, J = 7.6 Hz), 4.08 (dd), 4.05 (d, 1 H), 3.98-3.66 (m), 3.56-3.40 (m), 3.32 (t, 1 H), 1.82 (s, 3 H).

[0064] Test Example 1. Stimulatory effect of 6-sulfo-galacto-N-biose on dendritic cells Murine (BALB / cA) bone marrow-derived dendritic cells (0.3×10 6 Cells (100 cells / mL) were cultured for 12 hours (37°C, 5% CO2) in a medium containing 6-sulfo-galacto-N-biose or galacto-N-biose (final concentration 100 μg / mL), the cells were harvested by centrifugation, and the expression levels of cellular genes (IL-10, IL-12, IL-6, iNOS, RALDH2) were measured by qRT-PCR.

[0065] The results are shown in Figure 1. Stimulation with 6-sulfo-galacto-N-biose significantly increased gene expression of iNOS, which induces defense mechanisms against infection, IL-6, which promotes IgA antibody production, and IL-12, IL-10, and RALDH2, which induce and control differentiation into effector T cells.

[0066] Test Example 2. IgA production induction effect by 6-sulfo-galacto-N-biose Peyer's patch immune cells from mice (BALB / cA) (1.25 × 10 6 cells / mL) were cultured for 5 days (37°C, 5% CO2) in medium containing 6-sulfo-galacto-N-biose or galacto-N-biose (final concentration 150 μg / mL), and the amount of immunoglobulin A (IgA) in the supernatant was measured by ELISA.

[0067] The results are shown in Figure 2. The amount of IgA antibody secreted by stimulation with 6-sulfo-galacto-N-biose was significantly increased.

Claims

1. Galβ(1→3)Xxx 1 [Xxx 1 represents 6-sulfo-N-acetylamino sugar. ] or Galβ(1→3)Xxx 1 -Xxx 2 [Xxx 1 represents 6-sulfo-N-acetylamino sugar, and Xxx 2 represents any sugar.], a salt thereof, or a solvate thereof.

2. Xxx 1 The sugar, its salt, or a solvate thereof according to claim 1, wherein is 6-sulfo-N-acetylgalactosamine.

3. The sugar, its salt, or a solvate thereof according to claim 1, wherein the number of monosaccharide molecules constituting the sugar is 2 to 20.

4. The sugar, its salt, or solvate thereof according to claim 3, wherein the number of molecules is 2 to 5.

5. A composition comprising at least one selected from the group consisting of the saccharide according to any one of claims 1 to 4, a salt thereof, and a solvate thereof.

6. The composition of claim 5 in an orally ingestible form.

7. The composition according to claim 5, which is a food composition, a food additive, a health promoting agent, a nutritional supplement, a medicine, or a reagent.

8. The composition according to claim 5, for use in at least one selected from the group consisting of immune activation, protection against infection, and promotion of IgA production.

9. Galactose donor and Xxx 1 [Xxx 1 represents 6-sulfo-N-acetylamino sugar.] or Xxx 1 -Xxx 2 [Xxx 1 represents 6-sulfo-N-acetylamino sugar, and Xxx 2 represents any sugar.] in the presence of β-galactosidase.